Delivery Order SPE2DB20D3103-SPE2DB25FP4Z7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on August 28, 2025, with completion anticipated by September 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $12,330.68 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors on September 18, 2025, with an ultimate completion date of October 9, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus, representing a specialty...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on July 17, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody treatment indicated for systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on September 8, 2025, with completion targeted for September 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and lupus nephritis, representing a...
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a $18,496.02 delivery order to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injector on September 11, 2025, with an ultimate completion date of October 2, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody therapeutic used in treating systemic...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,987.78 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on May 13, 2025, with completion expected by June 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis, representing a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units on September 11, 2025, with an ultimate completion date of October 2, 2025. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,082.67 and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis,...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP4Z7Delivery Order
The Defense Logistics Agency awarded a $18,496.02 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 14, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune conditions, representing a specialized pharmaceutical product within the federal medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical prime vendor vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems and other federal customers worldwide. The company's continued selection for such contracts reflects its capability to meet competitive federal procurement requirements and support critical healthcare needs across the Department of Defense and related agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.5k | 7/14/25 |